{"id":"https://openalex.org/W4396587789","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po2-18-01","title":"Abstract PO2-18-01: Assessment of Initial Dosing and Dose Management of Sacituzumab Govitecan-hziy (SG) and How Dosing Practices Impact Duration of Therapy (DOT)","display_name":"Abstract PO2-18-01: Assessment of Initial Dosing and Dose Management of Sacituzumab Govitecan-hziy (SG) and How Dosing Practices Impact Duration of Therapy (DOT)","publication_year":2024,"publication_date":"2024-05-02","ids":{"openalex":"https://openalex.org/W4396587789","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po2-18-01"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs23-po2-18-01","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po2-18-01","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-po2-18-01","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109480860","display_name":"Vikram C. Gorantla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vikram Gorantla","raw_affiliation_strings":["1University of Pittsburgh Medical Center;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Pittsburgh Medical Center;","institution_ids":["https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026516796","display_name":"Erin Alwon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Erin Alwon","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082874612","display_name":"Mike Gart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Mike Gart","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101919660","display_name":"John Li","orcid":"https://orcid.org/0000-0002-2572-2136","observed_orcids":["https://orcid.org/0000-0002-2572-2136"]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"John Li","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044935022","display_name":"Simon Blanc","orcid":"https://orcid.org/0009-0006-9937-3553","observed_orcids":["https://orcid.org/0009-0006-9937-3553"]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Simon Blanc","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114104610","display_name":"Dawn Brenneman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Dawn Brenneman","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030423262","display_name":"Prateesh Varughese","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Prateesh Varughese","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104014717","display_name":"Justin Scott","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Justin Scott","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008320011","display_name":"Harvey I. Katzen","orcid":"https://orcid.org/0000-0001-6574-544X","observed_orcids":["https://orcid.org/0000-0001-6574-544X"]},"institutions":[{"id":"https://openalex.org/I4210104122","display_name":"Connect","ror":"https://ror.org/0170ys284","country_code":"NO","type":"nonprofit","lineage":["https://openalex.org/I4210104122"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Harvey Katzen","raw_affiliation_strings":["2Integra Connect"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Integra Connect","institution_ids":["https://openalex.org/I4210104122"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"9_Supplement","first_page":"PO2","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.12870000302791595,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.12870000302791595,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.06949999928474426,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.04320000112056732,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9620000123977661},{"id":"https://openalex.org/keywords/starting-dose","display_name":"starting dose","score":0.6179999709129333},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.9380000233650208},{"id":"https://openalex.org/keywords/treatment-duration","display_name":"treatment duration","score":0.925000011920929},{"id":"https://openalex.org/keywords/dose-management","display_name":"dose management","score":0.49900001287460327},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.6349999904632568},{"id":"https://openalex.org/keywords/ascent-trial","display_name":"ASCENT trial","score":0.6399999856948853},{"id":"https://openalex.org/keywords/chemotherapy-dosing","display_name":"chemotherapy dosing","score":0.43299999833106995},{"id":"https://openalex.org/keywords/precision-oncology","display_name":"precision oncology","score":0.44600000977516174},{"id":"https://openalex.org/keywords/de-identified-patient-data","display_name":"de-identified patient data","score":0.5569999814033508},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.35899999737739563},{"id":"https://openalex.org/keywords/dose-de-escalation","display_name":"dose de-escalation","score":0.5899999737739563},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.3269999921321869},{"id":"https://openalex.org/keywords/patient-reported-quality-of-life","display_name":"patient-reported quality of life","score":0.3540000021457672}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.9695578813552856},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6704117059707642},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3382064700126648},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.25987038016319275}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs23-po2-18-01","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po2-18-01","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-po2-18-01","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399770571","https://openalex.org/W4402692718","https://openalex.org/W1996545201","https://openalex.org/W4393993157","https://openalex.org/W4400350523","https://openalex.org/W4289885594","https://openalex.org/W4412393874","https://openalex.org/W4414865065","https://openalex.org/W2574293854","https://openalex.org/W4401395133"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"As":[2],"the":[3,43,53,66,78,89,136,227,235,247,255,326,443,478,503,542,606],"Phase":[4],"3":[5,544],"ASCENT":[6,545],"trial\u2019s":[7],"safety":[8],"analysis":[9],"found":[10,437],"that":[11,438],"a":[12,24,144,168,178,260,406,428,448,455,467],"10m/kg":[13],"dose":[14,46,55,69,81,110,114,121,125,238,261,266,293,331,407,429,446,461,481,486,507],"of":[15,68,80,96,105,113,124,146,163,207,210,239,265,292,329,502,505,518,547,583,589,599,605],"SG":[16,48,75,152,197,464,483],"resulted":[17],"in":[18,515,550],"better":[19],"efficacy":[20],"than":[21,451],"treatment":[22,205,243],"with":[23,74,132,196,200,231],"lower":[25,456],"dose,":[26],"this":[27,61],"examination":[28],"sought":[29,63],"to":[30,34,42,64,107,141,187,278,307,354,386,416,466,490,511,523],"use":[31,79,123],"real-world":[32,93],"data":[33,154],"evaluate":[35,108],"how":[36,52,77,525],"patients":[37],"(pts)":[38],"were":[39,139,165,185,198,301],"dosed":[40],"compared":[41,174,277,306,353,385,415],"recommended":[44,236,444,479],"starting":[45,54,109,120,237,330,445,457,480,506],"for":[47,71,129,268,280,295,312,341,358,373,391,402,422,472,482],"as":[49,51,116,118,214,222],"well":[50,117],"impacted":[56,83,127],"pt":[57,153,189,513],"DOT.1":[58],"In":[59,134,459],"addition,":[60,460],"assessment":[62,87,436],"understand":[65,512,524],"rate":[67,112,264,291],"reductions":[70,82,126,267,294,462,489],"pts":[72,101,130,138,194,229,281,327,342,359,374,403,440,493],"treated":[73,131,195,230],"and":[76,111,122,173,219,246,484,496,520,586,593],"DOT.":[84,529],"Methods:":[85],"This":[86],"utilized":[88,155],"Integra":[90],"Connect":[91],"PrecisionQ":[92],"de-identified":[94],"database":[95],"over":[97],"2":[98],"million":[99],"cancer":[100],"across":[102],"500":[103],"sites":[104],"care":[106],"reduction,":[115],"whether":[119],"DOT":[128,176,324,340,372,401,450],"SG.":[133],"analyzing":[135],"DOT,":[137],"required":[140],"have":[142,427],"had":[143,259,405,447],"follow-up":[145],"12":[147],"months":[148],"or":[149,216,224,252,286,318,365,397],"greater.":[150],"The":[151,263,290,322,338,370,399,435],"reflects":[156],"treatments":[157],"through":[158],"May":[159],"31,":[160],"2023.":[161],"Comparisons":[162],"proportions":[164],"conducted":[166],"using":[167,177,477],"two":[169],"sample":[170],"two-tailed":[171],"z-test":[172],"median":[175,323,339,371,400],"Wilcoxon":[179],"Rank":[180],"Sum":[181],"test.":[182],"Descriptive":[183],"analyses":[184,540],"used":[186],"summarize":[188],"demographic":[190],"statistics.":[191],"Results:":[192],"433":[193,228,256],"identified":[199,213,221],"an":[201],"average":[202],"age":[203],"at":[204,244,272,284],"start":[206],"59.6":[208],"(median":[209],"61);":[211],"17%":[212],"Black":[215],"African":[217],"American":[218],"62%":[220],"White":[223],"Caucasian.":[225],"Of":[226],"SG,":[232],"83%":[233],"received":[234,250,442,454],"10mg/kg,":[240],"13%":[241],"initiated":[242],"7.5mg/kg":[245,300,378],"remaining":[248],"5%":[249],"5mg/kg":[251,317,396],"less.":[253,398],"Among":[254],"pts,":[257],"37%":[258],"reduction.":[262],"those":[269,296,313,392,423,452,526],"who":[270,282,297,314,343,360,375,393,404,424,441,453],"started":[271,283,298,315,344,361,376,394],"10":[273],"mg/kg":[274,364],"was":[275,332,347,379,409],"35%":[276],"43%":[279],"7.5mg":[285],"less":[287,319,366],"(p":[288,320,367,431],">0.05).":[289,321],"on":[299,316,345,362,377,395,463,470,494],"39%":[302],"(N":[303,309,335,350,356,382,388,412,419],"=":[304,310,336,351,368,383,389,413,420],"57)":[305],"55%":[308],"18)":[311],"among":[325],"regardless":[328],"116":[333],"days":[334,349,381,411,418],"336).":[337],"10mg/kg":[346],"136":[348],"254)":[352],"77":[355],"=61)":[357],"7.5":[363],".012).":[369],"91":[380],"166)":[384],"58":[387],"17)":[390],"reduction":[408,430],"172":[410],"125)":[414],"89":[417],"190)":[421],"did":[425],"not":[426],"<":[432],"0.001).":[433],"Conclusion:":[434],"SG-treated":[439],"longer":[449,468],"dose.":[458],"contributed":[465],"time":[469],"therapy":[471,495,519],"pts.":[473],"These":[474],"findings":[475],"suggest":[476],"then":[485],"managing":[487],"via":[488],"help":[491],"keep":[492],"delay":[497],"disease":[498],"progression.":[499],"Further":[500],"evaluation":[501],"impact":[504,528],"would":[508],"be":[509],"needed":[510],"differences":[514],"prior":[516],"lines":[517],"hormonal":[521],"status":[522],"factors":[527],"[1]":[530],"Rugo,":[531],"H.S.,":[532],"Tolaney,":[533],"S.M.,":[534],"Loirat,":[535],"D.":[536],"et":[537],"al.":[538],"Safety":[539],"from":[541],"phase":[543],"trial":[546],"sacituzumab":[548],"govitecan":[549],"metastatic":[551],"triple-negative":[552],"breast":[553],"cancer.":[554],"npj":[555],"Breast":[556,610],"Cancer":[557,611,622],"8,":[558],"98":[559],"(2022).":[560],"https://doi.org/10.1038/s41523-022-00467-1":[561],"Citation":[562],"Format:":[563],"Vikram":[564],"Gorantla,":[565],"Erin":[566],"Alwon,":[567],"Mike":[568],"Gart,":[569],"John":[570],"Li,":[571],"Simon":[572],"Blanc,":[573],"Dawn":[574],"Brenneman,":[575],"Prateesh":[576],"Varughese,":[577],"Justin":[578],"Scott,":[579],"Harvey":[580],"Katzen.":[581],"Assessment":[582],"Initial":[584],"Dosing":[585,595],"Dose":[587],"Management":[588],"Sacituzumab":[590],"Govitecan-hziy":[591],"(SG)":[592],"How":[594],"Practices":[596],"Impact":[597],"Duration":[598],"Therapy":[600],"(DOT)":[601],"[abstract].":[602],"In:":[603],"Proceedings":[604],"2023":[607,613],"San":[608,616],"Antonio":[609],"Symposium;":[612],"Dec":[614],"5-9;":[615],"Antonio,":[617],"TX.":[618],"Philadelphia":[619],"(PA):":[620],"AACR;":[621],"Res":[623],"2024;84(9":[624],"Suppl):Abstract":[625],"nr":[626],"PO2-18-01.":[627]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2024-05-03T00:00:00"}